Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?

Am J Gastroenterol. 2011 Oct;106(10):1865-6. doi: 10.1038/ajg.2011.258.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Androstadienes / administration & dosage
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • Biomarkers / blood
  • Biomarkers, Tumor / blood
  • Breast Neoplasms / complications
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Drug Combinations
  • ErbB Receptors / drug effects
  • ErbB Receptors / metabolism
  • Female
  • Hepacivirus / drug effects*
  • Hepacivirus / isolation & purification
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Neoplasm Staging
  • Oxonic Acid / administration & dosage
  • Receptor, ErbB-2 / blood
  • Receptors, Estrogen / blood
  • Tegafur / administration & dosage
  • Trastuzumab

Substances

  • Androstadienes
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Antiviral Agents
  • Biomarkers
  • Biomarkers, Tumor
  • Drug Combinations
  • Receptors, Estrogen
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • ERBB2 protein, human
  • ErbB Receptors
  • Receptor, ErbB-2
  • exemestane
  • Trastuzumab